Mizuho analyst Uy Ear raised the firm’s price target on Acadia Pharmaceuticals to $20 from $19 and keeps a Neutral rating on the shares after the company hosed a call to discuss Friday’s FDA approval of Daybue in Rett syndrome. Profit taking and investors looking for a more catalyst-rich stock might have led to yesterday’s selloff, the analyst tells investors in a research note. The firm says the label was largely as expected while pricing came in better than expected.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ACAD:
- Acadia Pharmaceuticals price target raised to $21 from $19.40 at Citi
- Acadia Pharmaceuticals price target raised to $28 from $25 at H.C. Wainwright
- Acadia Pharmaceuticals announces FDA approval of DAYBUE for Rett syndrome
- Acadia Pharmaceuticals price target raised to $24 from $20 at Canaccord
- This ETF Has 67% Upside Potential, According to Analysts